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Prostate cancer is the most frequently diagnosed cancer in men and often requires surgery. Use of near infrared (NIR) technologies
to perform image-guided surgery may improve accurate delineation of tumor margins. To facilitate preclinical testing of such
outcomes, here we developed and characterized a PSMA-targeted small molecule, YC-27. IRDye 800CW was conjugated to YC-27
or an anti-PSMA antibody used for reference. Human 22Rv1, PC3M-LN4, and/or LNCaP prostate tumor cells were exposed to
the labeled compounds. In vivo targeting and clearance properties were determined in tumor-bearing mice. Organs and tumors
were excised and imaged to assess probe localization. YC-27 exhibited a dose dependent increase in signal upon binding. Binding
specificity and internalization were visualized by microscopy. In vitro and in vivo blocking studies confirmed YC-27 specificity. In
vivo, YC-27 showed good tumor delineation and tissue contrast at doses as low as 0.25 nmole. YC-27 was cleared via the kidneys
but bound the proximal tubules of the renal cortex and epididymis. Since PSMA is also broadly expressed on the neovasculature of
most tumors, we expect YC-27 will have clinical utility for image-guided surgery and tumor resections.
1. Introduction
Prostate cancer is the most frequently diagnosed cancer in
men, affecting one in six, and is a leading cause of cancer
mortality [1–4]. Current methods for prostate cancer detec-
tion include imaging by ultrasound andmultiparametricMRI
for guidance in biopsy procedures and single-photon emis-
sion computed tomography (SPECT) with 111In-capromab
pendetide (Prostascint) for evaluation and management of
the disease [5–7]. Dual modality imaging agents are being
developed to take advantage of radionuclide sensitivity and
the resolution of near infrared (NIR) fluorescence [8] for
possible use in pre- and intraoperative applications. Clinically
available NIR dyes (indocyanine green and methylene blue)
are contrast agents with no tumor specificity [9, 10]. However,
imaging resolution is increased using agents that couple
strong tumor-targeting properties with sensitive detection
and relatively rapid clearance [11]. Recent reports have
described the successful intraoperative use of small molecule
targeting agents in several types of cancer for evaluation of
tumor margins, image-assisted resection, and laparoscopic
removal of lymph nodes [12–18].
Effective targeting of tumor cells has been achieved by
use of a variety of agents that are designed to recognize
aspects of the tumor cell surface in a specific manner [11,
13, 19, 20]. Particularly promising results have been obtained
by targeting prostate-specific membrane antigen (PSMA), a
type II transmembrane glycoprotein also known as glutamate
carboxypeptidase II, and folate hydrolase I, which is basally
expressed by prostate epithelial cells and overexpressed in
primary and metastatic prostate cancer [3, 4, 15]. Moreover,
PSMA expression has been detected in a variety of other solid
tumors, specifically and strongly associated with endothelial
cells of the peritumoral and intratumoral neovasculature
[3, 4, 21, 22]. Thus, PSMA is an attractive molecular target,
both for advancing basic mechanistic studies of prostate
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cancer progression in preclinical models and for surgical
applications [15, 21–23].
Available tools for PSMA targeting include monoclonal
antibodies and a variety of small molecule or peptide ligands,
each of which has advantages and limitations associated with
its use [24]. Antibody-based probes are attractive because of
the high level of specificity for the target and the picomolar-
range affinities that can often be achieved. These properties,
coupled with a longer circulating half-life than that of
many small molecules, significantly lower the required dose
for optimal detection [25]. Slower clearance (2-3 days) of
monoclonal antibody probesmay be favorable for presurgical
routines, but this extended waiting period is then neces-
sary before sufficiently high tumor-to-background signal is
realized and surgery can be performed with confidence [11,
13, 20]. These probes are also potentially immunogenic. In
contrast, small molecule probes can often be generated with
nanomolar affinity ranges and rapid clearance rates that not
only facilitate tissue penetration but also minimize poten-
tial toxicity resulting from exposure times [26–28]. Several
groups have developed PSMA-specific small molecule urea-
based compounds that have been successfully applied to
optical imaging of tumor tissue [27–31].
In this report, we evaluate near infrared (NIR)
fluorescence-based imaging of prostate tumor cells that
were targeted by a small molecule PSMA targeting agent,
YC-27. Comparisons to a commercially available anti-
PSMA antibody were made to illustrate biodistribution
and clearance issues. Both molecules were labeled with
IRDye 800CW and characterized for specific binding to
PSMA-positive cells in culture, followed by an evaluation
of clearance and tumor-targeting efficacy in mice. Our
results support the specificity of PSMA targeting for tumor
detection, provide optimized conditions for its use in mice,
and suggest benefits to the use of YC-27 as a targeting agent
based on its pharmacokinetic properties.
2. Materials and Methods
2.1. Cell Culture, Materials, and Reagents. LNCaP and 22Rv1
human prostate carcinoma cells purchased from American
Type Culture Collection (Rockville, MD) were maintained
in RPMI 1640 medium containing 10% fetal bovine serum.
PC3M-LN4 cells, derived from PC3 human prostate ade-
nocarcinoma cells, were kindly provided by Dr. Isaiah J.
Fidler (MD Anderson Cancer Center, Houston, TX) and
maintained in minimal essential medium containing 10%
fetal bovine serum, sodiumpyruvate, and nonessential amino
acids. Human PSMA/FOLH1/NAALADase I antibody was
purchased from R & D Systems (Minneapolis, MN). DAPI
and TO-PRO-3 were purchased from Life Technologies
Corporation (Carlsbad, CA). Rabbit polyclonal 𝛽-tubulin
antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Fluoromount Reagent and poly-D-lysine
hydrobromide were obtained from Sigma-Aldrich Chemicals
(St. Louis, MO) and Zeba Spin Desalting Column was from
Thermo Fisher Scientific (Waltham, MA). Poly-D-lysine
coated 96-well plates were purchased from BD Biosciences
(Bedford, MA). Amino acid synthons, synthetic resin sup-
ports, and peptide coupling reagents (NovaBioChem) were
purchased from EMD Millipore (Billerica, MA). IRDye
800CW NHS ester was provided by LI-COR Biosciences
(Lincoln, NE). All other reagents for chemical synthesis,
purification, and analysis were purchased from Sigma-
Aldrich (Milwaukee,WI), VWR (Radnor, PA), GlenResearch
(Sterling, VA), andThermo Fisher Scientific (Waltham,MA).
High-performance liquid chromatography (HPLC) analysis
and purification were performed on an Agilent 1100 Series
HPLC with appropriate reverse-phase columns, Ultraviolet
and Visible (UV/Vis) spectral analysis was performed on an
Agilent 8453 Series Spectrophotometer, and low-resolution
mass spectrometry (LRMS) was performed using electro-
spray (ES) techniques on an Agilent 1100 Series LC/MSD
Trap (Agilent Technologies, Santa Clara, CA). The Odyssey
Classic Infrared Imaging System, Aerius Automated Infrared
Imaging System, and Pearl Impulse Small Animal Imager
were provided by LI-COR Biosciences (Lincoln, NE).
2.2. Synthesis and Labeling of YC-27 andAnti-PSMAAntibody.
The bioactive moiety of YC-27 was synthesized as previously
reported [28] and labeled with IRDye 800CW NHS ester
(YC-27 800CW) [28]. The analytical data for YC-27 from de
novo synthesis were consistent with earlier reported results
[28, 29] and the dye-to-protein ratio was 1 : 1. IRDye 800CW
anti-PSMA antibody (PSMA 800CW) was prepared by the
addition of IRDye 800CW NHS ester at 3 : 1 dye-to-antibody
molar ratio. The solution was incubated for 3 h at room
temperature followed by spin column purification to remove
any remaining unconjugated dye. The final product dye-to-
protein ratio was 1.9.
2.3. Microscopy. Three human prostate cancer cell lines
with different levels of PSMA expression were used to
evaluate localization and internalization of probes: PC3M-
LN4 (negative), 22Rv1 (low), and LNCaP (high) [32, 33].
PC3M-LN4 and 22Rv1 cells were incubated at 37∘C for 1 h
with 300 nM YC-27 800CW or 1 𝜇g PSMA 800CW. Cells
were rinsed and fixed with 4% formaldehyde for 20min
and nuclei stained with DAPI. Images were obtained by
fluorescence microscopy using an Olympus IX81 Inverted
Microscope equipped with a halogen bulb and NIR fil-
ters (EX:HQ760/40x, 790DCXR, EM:HQ830/50m; Chroma
Technology Corp., Rockingham, VT).
2.4. In Vitro Examination of YC-27 800CW in Cell Culture.
Human A431, MCF7, U87 GM, PC3M-LN4, and 22Rv1
cells were rinsed with PBS and lysed with Laemmli Sample
buffer. After electrophoresis, proteins were transferred to
a nitrocellulose membrane, blocked for 1 h with Odyssey
Blocking Buffer, and incubated with primary antibodies at
1 : 2000 dilution (PSMA 800CW and rabbit polyclonal 𝛽-
tubulin) for 1 h at room temperature with shaking. Proteins
were detectedwith IRDye 680RD-conjugated goat anti-rabbit
IgG secondary antibody (LICOR Biosciences) visualized on
an Odyssey Infrared Imaging System (LI-COR Biosciences).
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Binding and specificity of YC-27 800CW and PSMA
800CW were further evaluated by fluorescent cell-based
assays. 22Rv1, PC3M-LN4, and LNCaP cells were grown
to approximately 80% confluency in a 96-well microtiter
plate. Poly-D-lysine coated plates were required for LNCaP
assays. Growth media were replaced with media containing
increasing concentrations of PSMA 800CW only (0.01 to
5 𝜇g/mL), YC-27 800CW (0.1 nM to 1 𝜇M), unlabeled YC-
27 (0.026 nM to 50𝜇M, 1 : 5 dilution series) plus 28 nM YC-
27 800CW, and YC-27 800CW (28 nM) plus 2-PMPA, a
competitive inhibitor of the NAALADase activity of PSMA
(0.5 nM to 50 𝜇M, 1 : 10 dilution series). All treatments were
done in triplicate and incubated at 37∘C in 5% CO
2
for
approximately 15min. Wells were rinsed in 1x PBS and
stopped by fixing with 4% formaldehyde solution for 20min
followed by four washes in 1x PBS + 0.02% Triton X-
100 to remove unbound dye and permeabilize the cells.
The plates were blocked in Odyssey Blocking Buffer (LI-
COR Biosciences, Lincoln, NE) for 1 hour and incubated
for an additional hour with TO-PRO-3 DNA stain (diluted
1 : 5000) for normalization of cell number.Washing stepswere
repeated with Odyssey Buffer + 0.02% Tween-20 and the
plate was scanned with an Odyssey SA Automated Infrared
Imaging System. Quantification was achieved by ratiometric
analysis of the fluorescent intensities obtained from 700 nm
(representing cell number) and 800 nm (representing labeled
probe) channels. Binding (apparent 𝐾
𝑑
) and competition
(IC
50
) parameters were calculated by nonlinear curve fit
analysis using GraphPad Prism 5 (GraphPad Software, San
Diego, CA).
2.5. In Vivo Animal Imaging. Male SCID Hairless Out-
bred mice (SHO, Crl:SHO-PrkdcSCIDHrhr) were purchased
from Charles River (Willington, MA) and maintained on
a purified irradiated maintenance diet (AIN-93M) from
Harlan Teklad (Madison, WI). All experimental procedures
for animal use were previously reviewed and approved by
the Institutional Animal Care and Use Committee at the
University of Nebraska-Lincoln and conducted in accor-
dance with the Guide for the Care and Use of Labo-
ratory Animals published by the US National Institutes
of Health.
Six-week-old mice were implanted subcutaneously with
22Rv1 (PSMA positive, right flank) and PC3M-LN4 (PSMA
negative, left flank) cells (1 × 106 cells/100 𝜇L saline) and
maintained until tumor size reached approximately 3mm
in diameter. At this time, tumor-bearing animals received
either 1x PBS (100 𝜇L), IRDye 800CW carboxylate (1 nmol),
IgG 800CW (IgG 800CW, 75𝜇g), YC-27 800CW (1 nmol),
or PSMA 800CW (75 𝜇g) injected via the tail vein. Three
doses, 0.25, 0.5, and 1.0 nmol, were evaluated in mice
with 22Rv1 tumors (𝑛 = 3 per dose). Specificity was
further confirmed by inhibition with 2-PMPA. For this
experiment, preinjection of 2-PMPA (2𝜇g, intravenous
administration) was followed by YC-27 800CW dose (0.5
nmole). Images were captured 24 h after injection of all
compounds using the Pearl Impulse Small Animal imaging
system.
2.6. Organ and Tissue Analysis. After final imaging, animals
were sacrificed and tumors and organs were removed for
imaging to confirm signal content and assess agent targeting.
Tumors and organs were snap-frozen in OCT compound
for cryosectioning. Sections (8 𝜇m thickness) were scanned
using the Odyssey CLx imaging system to measure 800 nm
fluorescence signal. The 800 nm fluorescence signal per pixel
was used to compare targeting agent specificity and retention
in tissues.
3. Results
3.1. Western Blot Analysis and Microscopic Examination. We
first confirmed the selectivity of the PSMA-specific anti-
body chosen for our study reference using western anal-
ysis (Figure 1(a)). PSMA protein (85 kDa) was specifically
detected in the PSMA-expressing cell line, 22Rv1. No signif-
icant nonspecific binding was noted for the nonexpressing
cell lysates. Prostate tumor cell lines that were positive or
negative for PSMA expression (22Rv1 and PC3M-LN4, resp.)
were incubated with PSMA 800CW (1 𝜇g, Figures 1(b) and
1(c)) or YC-27 800CW (300 ng, Figures 1(d) and 1(e)) and
counterstained with DAPI to visualize nuclei. Both probes
bound the PSMA-expressing cell lines and showed negligible
binding to the nonexpressing cell line.
3.2. Cellular Specificity of YC-27 800CW. To evaluate the
affinity and targeting specificity of YC-27 800CW, we
performed cell-based dose response assays. Three human
prostate tumor cell lines were chosen based on differing
expression of PSMA. YC-27 800CW showed dose dependent
increases in fluorescence, indicating high affinity binding to
22Rv1 cells (apparent𝐾
𝑑
= 8 nM, Figure 2(a)). No significant
signal increase was obtained upon addition of YC-27 800CW
to the PSMA-negative cell line, PC3M-LN4 (Figure 2(a)).
Importantly, LNCaP cells, which express levels of PSMA that
are higher than those of other commercially available lines,
exhibited comparable affinity for YC-27 800CW (apparent
𝐾
𝑑
= 36 nM, Figure 2(b)) with a significantly higher (∼200-
fold) fluorescence intensity at saturation, reflecting a higher
number of binding sites for the probe on these cells.
Specificity was further confirmed by competition studies.
LNCaP cells were treated with YC-27 800CW in combination
with either unlabeled YC-27 (Figure 2(c)) or with 2-PMPA,
a potent competitive inhibitor of PSMA enzymatic activity
(Figure 2(d)). Both compounds inhibited effectively as seen
by dose response decreases in signal intensity. The IC
50
for unlabeled YC-27 and 2-PMPA were 1.7 𝜇M and 0.1 𝜇M,
respectively, confirming PSMA as the target for the small
molecule.
3.3. In Vivo Probe Performance. Male mice were injected
subcutaneously with 22Rv1 cells in the right flank and PC3M-
LN4 cells in the left for direct comparison of PSMA targeting
probes. As expected, animals receiving any of the three
control compounds 1x PBS, 800CW carboxylate, or IgG
800CW showed minimal retention in either tumor (white
arrows, Figures 3(a)–3(c)). Both YC-27 800CW and PSMA
4 Prostate Cancer
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Figure 1: Western blot and probe localization. Human A431, MCF7, U87 GM, PC3M-LN4, and 22Rv1 cell lysates were prepared for western
blot analysis (a) to confirm PSMA reactivity of anti-PSMA antibody candidate. PSMA 800CWdistinguished between 22Rv1 (PSMA positive)
and PC3M-LN4 (PSMA negative) prostate tumor cell lysates, with no signal detected for cell lysates of nonprostate origin (A431, MCF-7,
and U-87 MG). Microscopy images captured cell binding for PSMA 800CW ((b) and (c)) and YC-27 800CW ((d) and (e)) to 22Rv1 (PSMA
positive, (b) and (d)) and PC3M-LN4 (PSMA negative, (c) and (d)). Images were obtained by fluorescence microscopy using an Olympus
IX81 Inverted Microscope.
800CW bound the 22Rv1 tumor (white arrows, Figures 3(d)
and 3(e), resp.), while little or no signal was visible in the
PC3M-LN4 tumors. As anticipated, animals injected with
PSMA 800CW showed incomplete clearance of the probe at
the 24 h time point (Figure 3(e)).
Examination of excised liver, kidney, and tumors from
animals given YC-27 800CWand PSMA 800CW is presented
in Figures 4(a) and 4(b), respectively. As expected, YC-
27 800CW showed negligible signal in the liver and high
signal in the kidneys, indicating no significant liver retention.
PSMA 800CW on the other hand showed the opposite with
high fluorescent signal in the liver and low signal in the
kidneys indicating a higher liver retention. Both probes were
specific for the PSMA-expressing tumor, 22Rv1, with negli-
gible signal in the PC3M-LN4 tumor. Signals quantified in
sections frommultiple organs further supported these results
(Figure 4(c)). In general, all tissues retained higher levels of
PSMA 800CW, including the PC3M-LN4 tumor, which is
consistent with incomplete clearance of the free probe. Both
probes accumulated in the epididymis. In considering the
higher signal of PSMA 800CW in 22Rv1 tumors, liver, and
epididymis, it is important to recognize that the optimal
clearance and imaging time point for an antibody-based
probe is closer to 72 h rather than the 24 h time point that
was optimal for YC-27 800CW [2].
Sections of liver, kidney, testes, and epididymis, which
had higher signal retention, were examined in greater
detail (Figure 5). Fluorescence intensity of both control IgG
800CW and specific PSMA 800CW was high in liver sec-
tions (Figure 5(a)), consistent with the reported clearance
of antibody-based reagents [2]. Low signal was noted in
the kidney. YC-27 800CW exhibited significant signal in
the kidney, with little or no signal retention in the liver.
As noted previously, the epididymis showed residual signal
for both PSMA-specific probes and, to a lesser extent, the
labeled controls. Interestingly, YC-27 800CW showed strong
localized signal in the kidney renal cortex, which houses the
proximal tubules. A representative microscopic image of the
renal cortex region (40X; Figure 5(b)) showed specific signal
in the brush border housing the proximal tubules.
3.4. Minimal Effective Dose Determination for YC-27 800CW.
SCIDHairless mice bearing 22Rv1 (right flank, white arrows)
and PC3M-LN4 (left flank) xenografts received intravenous
injections of 0.25, 0.5, or 1.0 nmol YC-27 800CW or YC-
27 800CW (0.5 nmol) plus 2-PMPA (2 𝜇g). Animals were
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Figure 2: Immunofluorescent cell-based comparison of binding and inhibition. (a) 22Rv1 and PC3M-LN4 cells were incubated with YC-27
800CW (1 nM to 0.5𝜇M). Apparent 𝐾
𝑑
= 8 nM. 𝐾
𝑑
for PC3M-LN4 could not be determined. (b) LNCaP cells were incubated with YC-27
800CW (0.5 nM to 0.5𝜇M, apparent 𝐾
𝑑
= 36 nM). Competition of YC-27 800CW binding to LNCaP cells by unlabeled YC-27 ((c), IC
50
=
1.7 𝜇M) or inhibition by 2-PMPA preincubation ((d), IC
50
= 0.1 𝜇M).
imaged 24 h after injection and tumors excised for further
analysis. As shown in Figures 6(a) and 6(b), reasonable
tumor-to-background was achieved at the lowest dose of
0.25 nmol. To demonstrate that the observed signals were due
to specific binding of the YC-27 800CW probe to PSMA,
animals receiving 0.5 nmol of the probe were challenged
with 2-PMPA prior to probe injection. The resulting ∼50%
decrease in signal confirmed the probe bound to its intended
target in vivo.
4. Discussion
YC-27 is chemically optimized from a lead compound that
exploited the inhibitory properties of a PSMA-binding urea
scaffold [27, 28], which improved pharmacokinetics for
detection of prostate and nonprostate tumors [29]. In the
current report, we characterized a YC-27 based NIR conju-
gate and compared its properties to an antibody-based PSMA
targeting agent. Our cell-based and in vivo data confirmed
that the attachment of IRDye 800CW to YC-27 did not alter
its target binding characteristics and showed the conjugate
bound PSMA-positive cells and tumors with high affinity
and specificity. YC-27 800CW produced a strong, specific
fluorescent signal in PSMA-positive tumors of intact animals
within 24 h, leaving minimal nonspecific background signal.
At the cellular level, PSMA is known to be internalized
from its residence at the cell surface via clathrin-coated pits,
which are subsequently recycled to the surface to reexpose
PSMA [23, 34]. Our cell-based analysis confirmed that
YC-27 800CW successfully bound extracellular PSMA, and
fluorescence microscopy revealed that significant quantities
were specifically internalized by the PSMA-positive cells.The
endocytic internalization and recycling of the PSMA target
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Figure 3: Tumor imaging with YC-27 800CW. SCID Hairless mice implanted with 22Rv1 (right flank) and PC3M-LN4 (left flank) cells
received (a) 1X PBS, 100𝜇L; (b) 800CW carboxylate, 1 nmol; (c) IgG 800CW, 75𝜇g; (d) YC-27 800CW, 1 nmol (D/P = 1; SNR = 11.8); or (e)
PSMA 800CW, 75𝜇g (D/P = 1; SNR = 8.9), which was allowed to clear for 24 h prior to imaging on Pearl Impulse Imaging System. Signal is
presented in pseudocolor. All images were normalized to the same LUT. White arrows indicate the location of the 22Rv1 tumor. Inset panels
show the white light image of the mouse.
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Figure 4: Tissue distribution of fluorescence signal. Tissues were excised at endpoint from animals given YC-27 800CW (column (a)) or
PSMA 800CW (column (b)). Representative whole organs (liver, kidney, and tumors) were imaged on the Pearl Impulse and reviewed for
residual fluorescence of each probe 24 h after intravenous administration. (c) Tissue sections (8𝜇m; frozen) were prepared from muscle,
brain, intestine, lung, heart, liver, kidney, spleen, testes, epididymis, and tumors, 22Rv1 and PC3M-LN4. Sections were imaged on Odyssey
CLx (21𝜇m) and 800 nm signal intensity per pixel was plotted for both probes.
is a mechanism that has afforded significant tumor-targeting
sensitivity by other receptor-targetedNIR fluorescent probes,
such as IRDye 800CW EGF [35], because the fluorophore
label accumulates within the cell while the receptor is
returned to the surface for additional probe binding.
YC-27 800CW cleared quickly in intact animals, yielding
high tumor-to-background signal within 24 h. In contrast,
antibodies are known to have prolonged circulating half-
lives [11, 20, 36, 37], so it was not surprising that the
antibody-based agent PSMA 800CWdid not achieve optimal
clearance in this period. The clearance profiles were reflected
in the quantitative analysis of fluorescence accumulation
in excised organs and tissues, which demonstrated greater
signal in all tissues of animals receiving PSMA 800CW. YC-
27 800CW fluorescence was most prominent in the renal
cortex, particularly in the brush border housing the proximal
tubules. Several reports have found PSMA expressed in
mouse kidneys [38, 39], but the implications for clinical use
are unknown. Basal PSMA expression is also reported in
salivary gland, brain, and small intestine [40]. No significant
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Figure 5: Fluorescence signal retention in specific clearance organs. (a) Tissue sections from mice receiving 1X PBS, carboxylate 800CW,
IgG 800CW, PSMA 800CW, and YC-27 800CW were scanned on Odyssey CLx (21 micron). In all images, green indicates signals captured
at 800 nm and red represents autofluorescence at 700 nm. Colocalization of the signals is yellow. (b) Higher magnification image (40x) of
kidney renal cortex from YC-27 800CW treated mouse.
signal was detected 24 h after injection in the prostatic region
including the bladder. These distribution patterns support
future testing of YC-27 800CW for sensitive and specific
distinction between normal, benign, and malignant tissue.
The binding of YC-27 800CW noted in the epididymis may
be attributable to recognition of the probe by glutamate
receptors (GluR). Previously, it was suggested that GluR may
be involved in spermatogenesis, spermatozoa motility, and
testicular development [41, 42]. In addition, glutamate bind-
ing could be partially displaced by N-methyl-D-aspartate in
the seminal vesicles [42]. The small molecule, YC-27, has
a glutamate component that may be exposed and available
for receptor binding. Another potential explanation is that
epididymal signals for all labeled agents, probes, and controls
may result from a bottleneck in clearance through this highly
vascular region coinciding with the imaging time point.
Nonetheless, binding to the epididymis is not expected to
be problematic in prostate surgery since this tissue is usually
removed during prostatectomy.
It has been suggested that the long circulating time
exhibited by antibody-based fluorescent contrast agents
could be advantageous, because lower doses of the agent
would be needed [2, 11, 20, 43]. However, the dose
dependence of the small molecule, YC-27 800CW, showed
that 22Rv1 tumors were detectable with good tumor-to-
background using 0.25 nmol. Thus, rapid clearance of a
targeting agent does not compromise its efficacy when the
agent has high affinity for the target, and the rapid clearance
would be entirely compatible with clinical workflow.This has
important implications for translation, since visualization of
tumor margins at the primary site, unambiguous identifica-
tion of tumor-involved secondary sites [12, 13, 20, 44–46],
and image-guided real time localization of tumor-involved
nodes or residual tissue following resection [14, 47] could
potentially benefit long-term patient outcomes.
Currently, 111In-capromab pendetide (Prostascint), an
antibody that recognizes an intracellular epitope of PSMA,
is used as an imaging agent in SPECT. These scans are
useful in early phases of diagnosis or postsurgery but may
be a disadvantage in the operating suite where exposure to
ionizing radiation to patient and surgeon could occur. NIR-
labeled optical imaging agents are also gaining attention for
tumor resection of a variety of cancers [11, 13, 20, 48, 49].
Due to the cost of clinical trials, single agents with broad
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Figure 6: Specificity of YC-27 800CW for tumor imaging in vivo. SCID Hairless mice implanted with 22Rv1 (right flank, white arrows) and
PC3M-LN4 (left flank) cells received intravenous injections of 0.25, 0.5, or 1.0 nmol YC27-800CW or 2-PMPA (2 𝜇g) plus YC-27 800CW
(0.5 nmol). (a) Animals were imaged intact after 24 hours, using Pearl Impulse; (b) 22Rv1 tumor sections from each animal at endpoint were
imaged on Odyssey CLx; (c) signal intensity of each tumor was quantified and normalized to unit area. Intact animal images are presented
in pseudocolor. All images are normalized to the same LUT. Odyssey CLx images for tumor sections are shown in green (800 nm) and red
(700 nm) and standardized to the same LUT.
reactivity against a number of cancers are desirable because
this approach reduces preclinical toxicity work and develop-
ment of new GMPmanufacturing and formulation processes
for individual agents [50]. PSMA is broadly expressed on
the neovasculature of many solid tumors [3, 4, 21, 51], so
agents targeting this protein are good candidates for clinical
translation [21, 22], and it may prove valuable to add YC-
27 800CW to the toolkit. Use of NIR fluorophore-labeled
PSMA targeting agents produced 100% resection with no
residual positive margins in PSMA-positive tumor-bearing
animals, supporting the use of this approach for prostate
tumor resections [15]. Future studies will be needed to define
the broad tumor-targeting efficacy of YC-27-based agents for
solid tumors.
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